Biotech Firm Should Increase Sales by 20% This Year


March 11, 2022 ( Newswire) This immunotherapy company’s outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front

The Ratings Game: Chevron stock is now a relative sell after too much outperformance, analyst says

Previous article

AI Eye Podcast 669: Stocks discussed: (NYSE: $AI) (NasdaqGM: $VERI)

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News